The 2020 ESHO-Pyrexar Award presentation included the history and merits of Professor Niloy Datta, celebrating his achievements in the field of thermal oncology.  What follows the award presentation is nothing less than a Master Class in thermal oncology.  Dr. Datta shares highlights of his research and his vision for the pathway to hyperthermia expansion and success.

Along with presenting evidence of the increased value to the patient that hyperthermia brings, Dr. Datta also touches on the financial rationale of adding a thermal oncology program to your hospital.

Below find a summary of recently published works involving hyperthermia by Datta et al.

 A special thanks to Dr. Sennewald Medizintechnik for sponsoring the award and presentation.

The Sigma Treatment Base Unit

• RF power delivery subsystem.
• Proprietary, thermistor-based, thermometry subsystems.
• Computerized monitoring and control subsystems.
• Applicator subsystem that includes an applicator and patient support system.
• Various accessories, including a tissue equivalent QA lamp phantom that provides verification of the energy focus, pattern steering, and system operations.

The standard BSD-2000 has a maximum power output of 1300 watts. Currently sold throughout the U.S., Europe and Asia. And in the U.S. only under FDA sanctioned device exemption.

Download Brochure | Watch Video | BSD-2000 Model Comparison
RF Isolation Cage | Get a Quote | Instructions for Use

Choose from 3 sizes of interchangeable superficial applicators and take advantage of up to 24 interstitial antennas for use with brachytherapy.  System software provides monitoring and control of up to 8 temperature sensors.  Master power control adjustable at the touch of a button.

Download Brochure Instructions for Use

Phase II Prostate + Radiotherapy

Authors: Anscher MS, Samulski TV, Dodge R, Prosnitz LR, Dewhirst MW.
Publication: Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1059-65.

PURPOSE:
To determine the safety and efficacy of combined external beam irradiation and external regional hyperthermia in the treatment of adenocarcinoma of the prostate.

Introduction to Pyrexar Family of Hyperthermia systems. 2 page full color.  Original available upon request for translation.

The 32^nd Annual Meeting of the Society of Thermal Medicine (STM) concluded last week. The event was held at the happiest place on earth, on the edges of the Disney World resort complex in Orlando, Florida. Apropos locations as temperatures were well into the ’90s, for you thermal scientists around 35˚C, just shy of the hyperthermia therapeutic range.

The annual event attracts clinicians and researchers with exceptional guest speakers and abstracts presented by colleagues. One of those abstracts, “Integration of Deep Hyperthermia with MR Imaging,” presented by our own Paul Turner, CTO at Pyrexar Medical. From what I witnessed, this group is made up of dedicated, passionate professionals who care deeply about treating cancer. Even our after-hours, get-togethers were filled with lively debates on the best uses of thermal therapy — many conversations requiring a Ph.D., MD, and whiteboard to sufficiently follow.

Pyrexar was very proud to represent the BSD-500 and BSD-2000 product lines at the show, as they have become cornerstones of the thermal therapy modality. We felt very welcomed by the group and had the chance to meet some of the clinicians and researchers behind many of the successful clinical trials you can find on our website.

We are very excited for ICHO 2016 (International Congress of Hyperthermic Oncology) currently planned for New Orleans. According to Chris Lapine, Association Manager at Allen Press, next year's conference will host not only the Society of Thermal Medicine but also ESHO – European Society of Hyperthermic Oncology and the JSTM - Japanese Society for Thermal Medicine. This combination event only happens once every four years. 2016 is going to be a great event.

To learn more about STM visit their website www.thermaltherapy.org